初始Gleason分级对前列腺癌主动监测结局的影响
该回顾性研究纳入1990至2016年间接受主动监测且至少两次活检的1243例前列腺癌患者,其中初始Gleason 3+3者1119例(90%),3+4者124例(10%)。5年未调整的免再分级生存率两组均为49%,但Gleason 3+4组治疗-free生存率更低(49% vs 64%,p<0.01)。多因素分析显示初始分级与再分级风险降低(HR 0.66,95%CI 0.46-0.95)和治疗风险升高(HR 1.37,95%CI 1.01-1.85)相关。
要点
- 初始Gleason 3+4与再分级风险降低相关(HR 0.66,95%CI 0.46-0.95)。
- 初始Gleason 3+4与治疗风险升高相关(HR 1.37,95%CI 1.01-1.85)。
- 根治性前列腺切除术后,初始Gleason 3+4组2年无生化复发生存率更低(69% vs 93%,p=0.01)。
核心结论
- 诊断时Gleason 3+4与再分级、治疗和生化复发风险相关,高级别穿刺针数可能有助于对Gleason 3+4患者进行分层。
研究设计与样本
- 回顾性研究,纳入1990年至2016年间接受主动监测、初始Gleason 3+3或3+4且至少有两次活检的前列腺癌患者1243例。
主要发现
- 1243例中1119例(90%)初始活检为Gleason 3+3,124例(10%)为3+4。
- 5年未调整的免再分级生存率两组均为49%,Gleason 3+4组治疗-free生存率更低(49% vs 64%,p<0.01)。
- 多因素Cox分析显示,分级与再分级风险降低相关(HR 0.66,95%CI 0.46-0.95),与治疗风险升高相关(HR 1.37,95%CI 1.01-1.85)。
- 根治性前列腺切除术后,初始Gleason 3+4组未调整2年无生化复发生存率更低(69% vs 93%,p=0.01),复发风险更高(HR 3.67,95%CI 1.30-10.36)。
- 分级与转移(5年时<1%)或不良病理无关。
关键数值与推荐
- 敏感性分析中,单根高级别穿刺针与再分级风险降低相关,多根高级别穿刺针与治疗风险升高相关,高级别穿刺针数与生化复发无独立关联。
临床怎么用
- 部分Gleason 3+4前列腺癌患者可能适合作为主动监测候选者,但需要更长随访和评估更多患者。
局限性
- 选择偏倚
- 中危患者数量有限
- 随访时间长度
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Whether men with Gleason 3+4 prostate cancer are appropriate active surveillance (AS) candidates remains a matter of debate. OBJECTIVE: to evaluate the effects of initial Gleason grade 3+3 or 3+4 on clinical outcomes during AS. DESIGN, SETTING, AND PARTICIPANTS: We retrospectively reviewed outcomes for men on AS between 1990 and 2016 with Gleason 3+3 or 3+4 who had two or more biopsies. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We evaluated associations of diagnostic grade with reclassification (upgrade ≥ 3+4), treatment, metastasis, adverse surgical pathology, and biochemical recurrence (BCR) after deferred radical prostatectomy (RP), with a sensitivity analysis for the amount of pattern 4 disease. RESULTS AND LIMITATIONS: Of 1243 men, 1119 (90%) had Gleason 3+3 and 124 (10%) 3+4 on initial biopsy. The 5-yr unadjusted reclassification-free survival was 49% regardless of grade, while patients with Gleason 3+4 had lower treatment-free survival (49% vs 64%; p<0.01). On multivariate Cox analysis, grade was associated with lower risk of reclassification (hazard ratio [HR] 0.66, 95% confidence interval [CI] 0.46-0.95) and higher risk of treatment (HR 1.37, 95% CI 1.01-1.85). After RP, patients starting with Gleason 3+4 had lower unadjusted 2-yr BCR-free survival (69% vs 93%; p=0.01) and a higher risk of recurrence (HR 3.67, 95% CI 1.30-10.36). Grade was not associated with metastasis (<1% at 5 yr) or adverse pathology. In sensitivity analyses, a single high-grade core was associated with lower risk of reclassification and multiple high-grade cores were associated with a higher risk of treatment. The number of high-grade cores was not independently associated with BCR. Limitations include selection bias, a limited number of intermediate-risk patients, and length of follow-up. CONCLUSIONS: Gleason 3+4 at diagnosis was associated with risk of reclassification, treatment, and BCR. The number of high-grade cores may help in stratifying men with Gleason 3+4 disease. PATIENT SUMMARY: Some men with Gleason 3+4 prostate cancer may be appropriate surveillance candidates, but longer follow-up and evaluation of more patients are necessary.
引用
- Masic S, Cowan JE, Washington SL, et al. Effects of Initial Gleason Grade on Outcomes during Active Surveillance for Prostate Cancer. Eur Urol Oncol. 2018. PMID: 31158077. doi:10.1016/j.euo.2018.04.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。